48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohortAlfonso Cabello, Miguel Górgolas, Esmeralda Palmier et al.|PLoS ONE|2022Cited by 20
Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019–2021Laura Viñuela, Féderico García, Adolfo de Salazar et al.|Journal of Medical Virology|2023Cited by 7
Discovering HIV related information by means of association rules and machine learningLourdes Araujo, Xabier Kortajarena, Juan Martínez-Romo et al.|Scientific Reports|2022Cited by 5
Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA StudyAlfonso Cabello, Federico Pulido, Juan Carlos López Bernardo de Quirós et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2025Cited by 1
Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022–2024)Pablo Ryan, Juan González, Juan Berenguer et al.|Open Forum Infectious Diseases|2025Cited by 1